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Conclusion
References
Background
• Key roles for clinical pharmacist  caring for CKD patients includes:
• Medication management cost
• Managing complications (e.g. anaemia, CKD-MBD)
• Pharmacist led clinics (Medication review, Transplant clinic)
• Independent prescribing
• Since the publication of a review by Salgado et al (1), the prescribing 
practice is continually developing and embedding into clinical 
pharmacy practice. Moreover, the model of care and advancement in 
practice is changing and evolving. Hence, there is a need to update the 
review in collaboration with the original authors. 
Aim 
• The overall aim of the SR was to critically appraise, synthesize and present 
the available evidence for the structures, processes and related outcomes 
of clinical pharmacy practice in caring for patients with CKD.
Methods
• A SR protocol was registered with the international prospective register of 
systematic reviews (PROSPERO). (2)
• Databases searched from April 2010 to March 2017:
• PUBMED, CINAHL, IPA, SCOPUS
• Search strategy:
• A concept map was developed of relevant MESH related search 
terms. This was guided by terms from original review (e.g. CKD, 
RRT & clinical pharmacy, pharmaceutical services).
• The search was conducted on 07/06/2017.
• Quality assessment:
• Mixed methods appraisal tool (MMAT) tools (3), suitable for 
controlled and non-controlled studies, was used for all papers.
• Independent, screening of titles, abstracts, and full texts, as well as quality 
assessment was performed by SR team members.
Review Questions 
• What clinical pharmacy practice related resources (structures, e.g. the 
multidisciplinary team, clinical pharmacy skill mix and time allocation) are in 
place and how are these matched to healthcare needs and demands to 
enable provide care to CKD patients?
• What activities are performed (processes, e.g. medication review, 
prescribing) to care for patients with CKD, how and when are they 
performed? 
• What are the outcomes of the structure and the processes on the 
effectiveness (Economic, Clinical, and Humanistic Outcomes (ECHO) model) 
and efficiency of care provided? 
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Results
Figure 1: PRISMA flow chart for inclusion process
Results
• The search identified 37 relevant articles..
• There were 13 controlled studies and 24 uncontrolled studies involving 
10,016 participants. 
• The 37 studies included in the review were carried out in the USA (n = 8), 
Iran (n = 5), India (n = 3), France (n = 3), Spain (n = 3), Jordan (n = 2), Japan 
(n = 2), Nigeria, Australia, Germany, Netherlands, Indonesia, Singapore, 
Norway, Canada and the UK, with one study each.
• Majority of the papers were of ‘FAIR’ quality.
• Pharmacists intervention was the main focus of all the studies identified, 
but only 40.5%  focused on clinical outcomes. 
• Pharmacists were able to identify 4,244 drug therapy related problems in 
2,650 patients and made 2537 recommendations to different healthcare 
professionals with an acceptance rate varying from 33.3% to slightly 
above 95%.
• Few studies reported the clinical significance of the recommendations 
ranging from moderate to life-saving. 
There is still lack of good quality evidence of pharmacists role in caring for 
patients with CKD and the outcomes are diverse. Yet it is apparent with the best 
available evidence that pharmacists caring for patients with CKD may have 
positive impact on the outcomes of these patients.
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Figure 2: Stacked bar chart representing quality of quantitative Randomised Controlled Trials 
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6. Are there complete outcome data (80% or above), or acceptable response
rate (60% or above)?
5. In the groups being compared, are the participants comparable?
4. Are measurements appropriate regarding the exposure/intervention and
outcomes?
3. Are participants (organizations) recruited in a way that minimizes selection
bias?
2. Do the collected data allow address the research question or objectives?
1. Are there clear quantitative research questions or objectives?
Figure 3: Stacked bar chart representing quality of quantitative non-randomised studies
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6. Is there an acceptable response rate (60% or above)?
5. Are measurements appropriate (clear origin, or validity known, or standard
instrument)?
4. Is the sample representative of the population understudy?
3. Is the sampling strategy relevant to address the quantitative research
question?
2. Do the collected data allow address the research question or objectives?
1. Are there clear quantitative research questions or objectives?
Figure 4: Stacked bar chart representing quality of quantitative descriptive studies 
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